Faced With Criticism, Bayh Dole-like Act At Bay In India; Government Takes Up Closer Scrutiny (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Patenting of public-funded research for innovation - an idea mooted a few years ago by India's former science and technology minister Kapil Sibal reflecting mostly from the Bayh-Dole Act in the U.S. - is now pending scrutiny by the Parliamentary Standing Committee before enactment but in its two-year-long run up has unobtrusively created a deep divide among the rank and file of the Indian pharmaceutical industry
You may also be interested in...
Faced With Criticism, Bayh Dole-like Act "At Bay" In India; Government Takes Up Closer Scrutiny (Part 2 of 2)
MUMBAI - Patenting of public-funded research for innovation is now pending scrutiny by India's Parliamentary Standing Committee and has created a deep divide among the rank and file of the Indian pharmaceutical industry. Part one of this story questioned whether such a bill could logistically fit with India's present regulatory structure. In this second part, PharmAsia News interviews different sources on both sides of the divide on this Indian version of the Bayh-Dole Act in the U.S
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).